This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Imprimis Pharmaceuticals, Inc.
Drug Names(s): lidocaine/heparin, URG101
Description: URG101 is an intravesical combination of lidocaine (anesthetic) and heparin (anti-coagulant). The heparin, a glycosaminoglycan, coats the bladder wall augmenting natural heparinoids, which may be deficient on the surface of the urothelium. Heparin is not utilized in this application for its anti-coagulant properties. Heparinoids comprise part of the mucus layer of the urothelium and help to limit urinary toxins from penetrating the underlying tissues thereby preventing pain, tissue inflammation and muscle spasms.
Urigen and Oceana
In December 2009, Urigen Pharmaceuticals announced that the Company and Oceana Therapeutics agreed to jointly prepare for a meeting with the U.S. Food & Drug Administration regarding the continued development of URG101.
In April 2010, Urigen Pharmaceuticals and Oceana Therapeutics terminated their consulting agreement.
Urigen and Imprimis
In October 2014, Imprimis announced that it has entered into a license agreement, under which Imprimis acquired the US rights to commercially compound a patented combination of alkalized lidocaine and heparin from Urigen.
Under the terms of the agreement, Imprimis shall pay Urigen tiered royalties based on net product sales with a minimum annual payment per unit for each prescription dispensed. The license does not require any cash payment by Imprimis upon execution. The license is non-exclusive for a period of six months, at which time Imprimis has the sole right to convert to an exclusive...See full deal structure in Biomedtracker
Partners: Urigen Pharmaceuticals, Inc.
Additional information available to subscribers only: